Dr. Maloney on Future Treatment With CAR T-Cell Therapy

Video

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Patients need to be referred to treatment with CAR T-cell therapy at the appropriate time, states Maloney. The results will continue to be more beneficial as the studies move earlier in the disease course.

According to Maloney, it will take some time before CAR T-cell therapy is seen in oncology centers, as there is a learning curve associated with managing these patients.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine